Geron (GERN) Non Operating Income (2019 - 2026)
Geron's (GERN) quarterly Non Operating Income came in at -$74000.0 in Q1 2026, up 10.84% year-on-year from -$66760.9 in Q1 2025, and down 5.71% quarter-over-quarter from -$70000.0 in Q4 2025.
Geron (GERN) Non Operating Income (2019 - 2026) Analysis & Trends
Geron has disclosed Non Operating Income across 8 years of filings, most recently posting -$74000.0 for Q1 2026.
- Non Operating Income for Q1 2026 came in at -$74000.0, up 10.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$366000.0 (down 42.41% YoY), and the FY2025 annual result was -$375000.0, down 58.9% from the prior year.
- Non Operating Income came in at -$74000.0 for Q1 2026 at Geron, down from -$70000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.1 million in Q2 2022 to a low of -$161000.0 in Q3 2025.
- The 5-year median for Non Operating Income is -$62000.0 (2024), against an average of $17294.1.
- Across the five-year window, Non Operating Income surged 6629.41% in 2022 and tumbled 472.73% in 2024, its largest moves.
- Geron's Non Operating Income stood at $86000.0 in 2022, then tumbled by 52.33% to $41000.0 in 2023, then slumped by 217.07% to -$48000.0 in 2024, then sank by 45.83% to -$70000.0 in 2025, then slipped by 5.71% to -$74000.0 in 2026.
- The last three Non Operating Income figures came in at -$74000.0 (Q1 2026), -$70000.0 (Q4 2025), and -$161000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 9.35 Mn |
| 10 | Geron | 753,046.88 | 753,046.88 | - | -74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Sep 30, 2025 | -161,000.00 |
| Jun 30, 2025 | -61,000.00 |
| Mar 31, 2025 | -83,000.00 |
| Dec 31, 2024 | -48,000.00 |
| Sep 30, 2024 | -63,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | -92,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Sep 30, 2022 | -138,000.00 |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | -77,000.00 |
| Jun 30, 2021 | -17,000.00 |